In one study, CDK1 inhibitors contributed to a marked reduction in the proportion of cells in S and G2/M phases of the cell cycle in PDAC tumor cell models; targetting CDK1 also showed promising anticancer activity in pancreatic cancer cells [56,57]. Here, CDK1 is linked to familial pancreatic carcinoma.